comprehensive -WSS

comprehensive

author：entertainment 2025-09-06 05:03:12 - browse：9776

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Live blog: Hearing on CRISPR

knowledge

WSS

With clinical trial data readouts, here's how to spot spin

How to pay for weight loss drugs and save Medicare

Travis Kelce and the trap of celebrity vaccine endorsements

Key Senate panel to consider PBM, drug pricing reform package

Flagship Pioneering launches a new biotech in two countries

DeepMind touts AlphaFold's new skills as protein folding AI models face off

hotspot

comprehensive

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Live blog: Hearing on CRISPR

Alkermes shareholders re

U.K. Biobank has 500,000 peoples' genome sequences available

Hepatitis C has a cure — but many Americans still lack access to it

What is microchimerism and how does it affect maternal health?

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Peter Hotez and the public health issue of online harassment

How to convince healthy people to buy insurance

focus

All of Us, NIH's precision medicine initiative, gets a big boost

How neuroscience research could help beat back brain cancer

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Rep. Raul Ruiz on the physician shortage and more

U.K. Biobank has 500,000 peoples' genome sequences available

Diagnostic tests are hitting their mathematical limits

Wikipedia

knowledge

entertainment

hotspot